Dean Li, Merck Research Laboratories president

The crown jew­el in Mer­ck’s $11.5B Ac­celeron buy­out just cleared a piv­otal PhI­II

Mer­ck con­sis­tent­ly spot­light­ed the multi­bil­lion-dol­lar sales po­ten­tial of so­tater­cept, the lead drug in Ac­celeron’s pipeline, as it ex­plained to in­vestors why it wa­gered $11.5 bil­lion to ac­quire the biotech late last year.

The phar­ma gi­ant is now one step clos­er to ful­fill­ing that po­ten­tial.

As promised, Mer­ck has un­veiled topline da­ta from the piv­otal Phase III STEL­LAR tri­al, which it said met the pri­ma­ry end­point as well as all but one of the nine sec­ondary end­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.